Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;15(4):355-365.
doi: 10.1159/000509846. Epub 2020 Jul 21.

Genomic Signatures in Luminal Breast Cancer

Julian Puppe  1 , Tabea Seifert  1 , Christian Eichler  1 , Henryk Pilch  1 , Peter Mallmann  1 , Wolfram Malter  1
Affiliations
Review

Genomic Signatures in Luminal Breast Cancer

Julian Puppe et al. Breast Care (Basel). 2020 Aug.

Abstract

Background: Breast cancer is a very heterogeneous disease and luminal breast carcinomas represent the hormone receptor-positive tumors among all breast cancer subtypes. In this context, multigene signatures were developed to gain further prognostic and predictive information beyond clinical parameters and traditional immunohistochemical markers.

Summary: For early breast cancer patients these molecular tools can guide clinicians to decide on the extension of endocrine therapy to avoid over- and undertreatment by adjuvant chemotherapy. Beside the predictive and prognostic value, a few genomic tests are also able to provide intrinsic subtype classification. In this review, we compare the most frequently used and commercially available molecular tests (OncotypeDX®, MammaPrint®, Prosigna®, EndoPredict®, and Breast Cancer IndexSM). Moreover, we discuss the clinical utility of molecular profiling for advanced breast cancer of the luminal subtype.

Key messages: Multigene assays can help to de-escalate systemic therapy in early-stage breast cancer. Only the Oncotype DX® and MammaPrint®test are validated by entirely prospective and randomized phase 3 trials. More clinical evidence is needed to support the use of genomic tests in node-positive disease. Recent developments in high-throughput sequencing technology will provide further insights to understand the heterogeneity of luminal breast cancers in early-stage and metastatic disease.

Keywords: Breast cancer; Gene expression; Luminal breast cancer; Predictive biomarker; Prognostic biomarker.

PubMed Disclaimer

Conflict of interest statement

Wolfram Malter received honoraria from Genomic Health (advisory board), Pfizer (advisory board), Novartis (advisory board), NanoString, Celgene, and Roche. Tabea Seifert, Christian Eichler, Henryk Pilch, Peter Mallmann, and Julian Puppe have no conflict of interests to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003 Jul;100((14)):8418–23. - PMC - PubMed
    1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug;406((6797)):747–52. - PubMed
    1. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. METABRIC Group The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012 Apr;486((7403)):346–52. - PMC - PubMed
    1. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 Aug;28((8)):1700–12. - PMC - PubMed
    1. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics. 2012;6:289–97. - PMC - PubMed